Please contact us for pricing and bulk order inquiries
GMP Grade(Clinical / Commercial Use)
Request a Quote
Please contact us for pricing and bulk order inquiries
MSCap Research Data
Luciferase Expression in HEK293 Cell
Luciferase Expression
Conventional Cap1
MSCap Family
Research data: Exvivo study on tumor growth inhibition
This result was obtained under specific research conditions and is provided for research reference only. It does not represent approved therapeutic claims.
01
02
03
04
05
06
07
Control
Conventional Cap 1
MSCap Family
mRNA Plarform Technology
CAPPING
TECHNOLOGY
Capping technology plays a pivotal role in the development
of mRNA therapeutics by stabilizing transcripts, protecting them
from exonuclease degradation, and ensuring efficient ribosomal
recognition.
Modified nucleosides are essential for enhancing the performance
of mRNA therapeutics. By reducing innate immune activation and
increasing transcript stability, they enable higher translational efficiency
and prolonged protein expression.
3’ end modification is a critical strategy to enhance the stability and
durability of mRNA transcripts. By protecting against exonuclease
degradation and optimizing poly(A) tail structures, these modifications
prolong mRNA half-life and sustain protein expression.
